299 related articles for article (PubMed ID: 27374030)
1. [Clinical and biological prognostic factors in relapsed acute myeloid leukemia patients].
Yébenes-Ramírez M; Serrano J; Martínez-Losada C; Sánchez-García J
Med Clin (Barc); 2016 Sep; 147(5):185-191. PubMed ID: 27374030
[TBL] [Abstract][Full Text] [Related]
2. Leukemia-associated aberrant immunophenotype in patients with acute myeloid leukemia: changes at refractory disease or first relapse and clinicopathological findings.
Cui W; Zhang D; Cunningham MT; Tilzer L
Int J Lab Hematol; 2014 Dec; 36(6):636-49. PubMed ID: 24602197
[TBL] [Abstract][Full Text] [Related]
3. Clonal evolution detected with conventional cytogenetic analysis is a potent prognostic factor in adult patients with relapsed AML.
Shimizu H; Yokohama A; Ishizaki T; Hatsumi N; Takada S; Saitoh T; Sakura T; Nojima Y; Handa H
Hematol Oncol; 2018 Feb; 36(1):252-257. PubMed ID: 28378367
[TBL] [Abstract][Full Text] [Related]
4. Cytogenetic clonal heterogeneity is not an independent prognosis factor in 15-60-year-old AML patients: results on 1291 patients included in the EORTC/GIMEMA AML-10 and AML-12 trials.
Baron F; Stevens-Kroef M; Kicinski M; Meloni G; Muus P; Marie JP; Halkes CJM; Thomas X; Vrhovac R; Specchia G; Lefrere F; Sica S; Mancini M; Venditti A; Hagemeijer A; Becker H; Jansen JH; Amadori S; de Witte T; Willemze R; Suciu S
Ann Hematol; 2018 Oct; 97(10):1785-1795. PubMed ID: 29926156
[TBL] [Abstract][Full Text] [Related]
5. Immunophenotypic and cytogenetic changes in acute leukaemia at relapse.
Hur M; Chang YH; Lee DS; Park MH; Cho HI
Clin Lab Haematol; 2001 Jun; 23(3):173-9. PubMed ID: 11553058
[TBL] [Abstract][Full Text] [Related]
6. [Minimal residual disease detection in acute leukemia patients by flow cytometric assay of cross-lineage antigen expression].
Cho YU; Park CJ; Cha CH; Chi HS; Jang S; Kim MJ; Lee KH; Lee JH; Lee JH; Seo JJ; Im HJ
Korean J Lab Med; 2010 Dec; 30(6):533-9. PubMed ID: 21157135
[TBL] [Abstract][Full Text] [Related]
7. Molecular Minimal Residual Disease in Acute Myeloid Leukemia.
Jongen-Lavrencic M; Grob T; Hanekamp D; Kavelaars FG; Al Hinai A; Zeilemaker A; Erpelinck-Verschueren CAJ; Gradowska PL; Meijer R; Cloos J; Biemond BJ; Graux C; van Marwijk Kooy M; Manz MG; Pabst T; Passweg JR; Havelange V; Ossenkoppele GJ; Sanders MA; Schuurhuis GJ; Löwenberg B; Valk PJM
N Engl J Med; 2018 Mar; 378(13):1189-1199. PubMed ID: 29601269
[TBL] [Abstract][Full Text] [Related]
8. Monosomal karyotype as an adverse prognostic factor in patients with acute myeloid leukemia treated with allogeneic hematopoietic stem-cell transplantation in first complete remission: a retrospective survey on behalf of the ALWP of the EBMT.
Brands-Nijenhuis AV; Labopin M; Schouten HC; Volin L; Socié G; Cornelissen JJ; Huynh A; Ljungman P; Malard F; Esteve J; Nagler A; Mohty M
Haematologica; 2016 Feb; 101(2):248-55. PubMed ID: 26589909
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of CEBPA mutations and BAALC expression in acute myeloid leukemia Egyptian patients with normal karyotype.
El-Sharnouby JA; Ahmed LM; Taha AM; Kamal O
Egypt J Immunol; 2008; 15(1):131-43. PubMed ID: 20306678
[TBL] [Abstract][Full Text] [Related]
10. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study.
Terwijn M; van Putten WL; Kelder A; van der Velden VH; Brooimans RA; Pabst T; Maertens J; Boeckx N; de Greef GE; Valk PJ; Preijers FW; Huijgens PC; Dräger AM; Schanz U; Jongen-Lavrecic M; Biemond BJ; Passweg JR; van Gelder M; Wijermans P; Graux C; Bargetzi M; Legdeur MC; Kuball J; de Weerdt O; Chalandon Y; Hess U; Verdonck LF; Gratama JW; Oussoren YJ; Scholten WJ; Slomp J; Snel AN; Vekemans MC; Löwenberg B; Ossenkoppele GJ; Schuurhuis GJ
J Clin Oncol; 2013 Nov; 31(31):3889-97. PubMed ID: 24062400
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of chromosomal abnormalities at relapse in children with relapsed acute myeloid leukemia: A retrospective cohort study of the Relapsed AML 2001/01 Study.
Klein K; Beverloo HB; Zimmermann M; Raimondi SC; von Neuhoff C; de Haas V; van Weelderen R; Cloos J; Abrahamsson J; Bertrand Y; Dworzak M; Fynn A; Gibson B; Ha SY; Harrison CJ; Hasle H; Elitzur S; Leverger G; Maschan A; Razzouk B; Reinhardt D; Rizzari C; Smisek P; Creutzig U; Kaspers GJL
Pediatr Blood Cancer; 2022 Jan; 69(1):e29341. PubMed ID: 34532968
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive flow cytometry phenotype in acute leukemia at diagnosis and at relapse.
Li X; Du W; Liu W; Li X; Li H; Huang SA
APMIS; 2010 May; 118(5):353-9. PubMed ID: 20477810
[TBL] [Abstract][Full Text] [Related]
13. Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukemia before and after allogeneic hemopoietic stem cell transplantation.
Bastos-Oreiro M; Perez-Corral A; Martínez-Laperche C; Bento L; Pascual C; Kwon M; Balsalobre P; Muñoz C; Buces E; Serrano D; Gayoso J; Buño I; Anguita J; Diéz-Martín JL
Eur J Haematol; 2014 Sep; 93(3):239-46. PubMed ID: 24702162
[TBL] [Abstract][Full Text] [Related]
14. [Immunophenotyping in adult acute myeloid leukemia: which prognostic value?].
Ben Salah N; Gouider E; Aounallah Skhiri H; El Borgi W; Jouabli M; Ben Lakhal F; Jeddi R; Hafsia R
Tunis Med; 2012; 90(8-9):602-5. PubMed ID: 22987373
[TBL] [Abstract][Full Text] [Related]
15. Outcome of children with acute myeloid leukaemia (AML) experiencing primary induction failure in the AIEOP AML 2002/01 clinical trial.
Quarello P; Fagioli F; Basso G; Putti MC; Berger M; Luciani M; Rizzari C; Menna G; Masetti R; Locatelli F
Br J Haematol; 2015 Nov; 171(4):566-73. PubMed ID: 26223157
[TBL] [Abstract][Full Text] [Related]
16. Analysis of hematogones in bone marrow from acute myeloid leukaemia cases posttherapy.
Zheng J; Du W; Yao J; You Y; Li W; He Y; Li X; Liu W; Wu Y; Hu Y; Jin R; Zou P; Huang S; Hu Y; Zhang M
Eur J Clin Invest; 2013 Nov; 43(11):1140-6. PubMed ID: 23992300
[TBL] [Abstract][Full Text] [Related]
17. The clinical significance of negative flow cytometry immunophenotypic results in a morphologically scored positive bone marrow in patients following treatment for acute myeloid leukemia.
Ouyang J; Goswami M; Tang G; Peng J; Ravandi F; Daver N; Routbort M; Konoplev S; Lin P; Medeiros LJ; Jorgensen JL; Wang SA
Am J Hematol; 2015 Jun; 90(6):504-10. PubMed ID: 25732229
[TBL] [Abstract][Full Text] [Related]
18. Cytogenetic studies of 103 patients with acute myelogenous leukemia in relapse.
Garson OM; Hagemeijer A; Sakurai M; Reeves BR; Swansbury GJ; Williams GJ; Alimena G; Arthur DC; Berger R; de la Chapelle A
Cancer Genet Cytogenet; 1989 Jul; 40(2):187-202. PubMed ID: 2766243
[TBL] [Abstract][Full Text] [Related]
19. Not the presence but the amount of clonal DNA detectable in remission of acute myeloid leukemia is predictive for relapse.
Reif SW; Wiesner D; Duell T; Mittermueller J; Schmetzer HM
Eur J Haematol; 2001 Oct; 67(4):207-20. PubMed ID: 11860441
[TBL] [Abstract][Full Text] [Related]
20. Clinical impact of leukemic blast heterogeneity at diagnosis in cytogenetic intermediate-risk acute myeloid leukemia.
Hoffmann MH; Klausen TW; Boegsted M; Larsen SF; Schmitz A; Leinoe EB; Schmiegelow K; Hasle H; Bergmann OJ; Sorensen S; Nyegaard M; Dybkaer K; Johnsen HE
Cytometry B Clin Cytom; 2012 May; 82(3):123-31. PubMed ID: 22328535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
